Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance suffered a negative impact of $700 million to $750 million as the company sustained a major loss of global business from the surge of cases of the coronavirus strain Covid-19 around the world that caused its customers to shelter in their homes.

Walgreens Takes $700M Hit From Coronavirus ‘Stay At Home’ Orders

Walgreens Boots Alliance Inc. WBA, +0.16% stock fell 3.1% in Thursday premarket trading after the pharmacy retailer reported third-quarter earnings that missed expectations and reported a COVID-19-related sales impairment.

Walgreens stock falls after reporting $2 billion impairment due to COVID-19

Walgreens Boots Alliance said Thursday its fiscal third quarter results were hurt by fewer people going to the doctor and getting prescriptions and by higher costs during the pandemic.

Walgreens swings to a loss as coronavirus drives up costs, lowers doctor visits

Shares of Walgreens Boots Alliance (NASDAQ:WBA) fell 2.2% in pre-market trading after the company reported Q3 results.

Walgreens Boots Alliance: Q3 Earnings Insights

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2020, which ended May 31, 2020.

Walgreens Boots Alliance Reports Fiscal 2020 Third Quarter Results

Walgreens plans to open full-service doctors' offices in hundreds of its stores across the US during the next five years.

Welcome to Walgreens. The doctor will be with you soon

VillageMD is going to open between 500 and 700 doctors' offices inside of Walgreens (WBA) stores over the next five years.
The post VillageMD to Open 500 to 700 Walgreens Doctors’ Offices appeared first on InvestorPlace.

VillageMD to Open 500 to 700 Walgreens Doctors’ Offices

Walgreens will open hundreds of full-service doctor offices inside its stores.

Walgreens Expands Focus on Medical Care With VillageMD Deal

Walgreens stock rose on news it will build up to 700 full-service primary care clinics in its retail stores within five years in partnership with VillageMD.

Dow Jones Stock Laggard Walgreens Launches Plan To Stay Relevant, Counter CVS Health

Walgreens Boots Alliance (NASDAQ: WBA) shares are trading higher on Wednesday after the company announced it partnered with VillageMD to open 500-700 full-service doctor offices within the next five years.

Why Walgreens Boots Alliance's Stock Is Trading Higher Today

Walgreens Boots Alliance Plc said on Wednesday it had partnered with primary care provider VillageMD to open doctor offices attached to its drugstores across the United States, as the pharmacy chain looked to expand its healthcare services.

Walgreens partners with VillageMD to open primary care clinics at drug stores

The convergence of sectors within healthcare continued Wednesday with the announcement that Walgreens, the nation’s second-largest pharmacy chain, will open full-service doctor’s offices in up to 700 locations in the next five years in a deal that gives Walgreens a $1 billion stake in VillageMD.

Walgreens To Bring Doctors Into 700 Pharmacy Locations

The Walgreens Boots Alliance Inc (NASDAQ:WBA) please stand up pharmacy chain seems to be selling at a deep discount, many gurus have positions in it and it pays an attractive dividend.

Walgreens Boots: A Bargain Stock, But at What Price?

Shares of Walgreens Boots Alliance Inc. WBA, -2.17% were up 2.4% in premarket trading on Wednesday after the pharmacy chain said it will take a 30% stake in VillageMD as part of its plans to open up to 700 VillageMD primary care practices at Walgreens locations.

Walgreens stock rises on plans to open 700 primary care practices

Under the deal, VillageMD will staff and run primary-care clinics in 500 to 700 stores over the next five years.

Walgreens strikes deal with primary-care company to open doctor offices in hundreds of drugstores

Walgreens will invest $1 billion in VillageMD to  open ‘500 to 700’ physician-staffed clinics inside its drugstores in more than 30 U.S. markets within the next five years.

Walgreens To Pay VillageMD $1 Billion To Open 500 Primary Care Clinics

Amazon

Walgreens: A Prime Candidate For Amazon

Walgreens stock has been uninspiring heading into earnings season. You shouldn't expect too much from WBA.

Does Walgreens Stock Need a Positive Earnings Surprise to Move Higher?

Chevron

Merck

Pfizer

Exxon Mobil

This simple strategy has done reasonably well in the past, but it's getting pounded this year.

Dogs of the Dow: Why 2020 Is Sending This Popular Strategy to the Doghouse

Walgreen Boots' (WBA) international businesses in the third quarter is likely to have suffered a huge blow with international trade coming almost to a standstill.

Pharmaceutical Wholesale to Aid Walgreens' (WBA) Q3 Earnings?

Walgreens stock is trading near a seven-year low ahead of Thursday's quarterly report, failing to benefit from a historic recovery wave.

Walgreens Stock Stuck in the Mud Ahead of Earnings

Bed Bath & Beyond

Levi Strauss

Paychex

Here, 24/7 Wall St. offers a preview of what to expect from some of the most anticipated quarterly results due this week.

Bed Bath & Beyond, Levi Strauss, Walgreens and More Earnings Coming This Week

Automatic Data Processing

Bank of America

Enterprise Products Partners

General Dynamics

Johnson & Johnson

Prudential Financial

Toronto-Dominion Bank

Tyson Foods

ViacomCBS

This article is part of our monthly series, where we highlight five companies that are large cap, relatively safe, dividend paying, and are offering large discounts to their historical norms.

5 Safe And Cheap Dividend Stocks To Invest In (July 2020)

Intel

3 Ridiculously Cheap Dividend Stocks to Buy Today

Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Walgreens Stock (WBA)